CAS 2443767-35-7

Formel: C25H28ClN7O2S

InChl: InChI=1S/C25H28ClN7O2S/c1-33(2)11-4-12-35-19-7-8-21-22(14-19)29-16-30-23(21)27-10-9-20-15-28-25(36-20)32-24(34)31-18-6-3-5-17(26)13-18/h3,5-8,13-16H,4,9-12H2,1-2H3,(H,27,29,30)(H2,28,31,32,34)

InChI Key: MMVLETOTGHDVPQ-UHFFFAOYSA-N

SMILES: CN(C)CCCOC1=CC2=C(C=C1)C(=NC=N2)NCCC3=CN=C(S3)NC(=O)NC4=CC(=CC=C4)Cl

1-(3-Chlorophenyl)-3-(5-(2-((7-(3-(Dimethylamino)Propoxy)Quinazolin-4-Yl)Amino)Ethyl)Thiazol-2-Yl)Urea

CAS: 2443767-35-7

1-(3-Chlorophenyl)-3-(5-(2-((7-(3-(Dimethylamino)Propoxy)Quinazolin-4-Yl)Amino)Ethyl)Thiazol-2-Yl)Urea

Formel: C₂₅H₂₈ClN₇O₂S

Reinheit: 98.45%

Molekulargewicht: 526.05

Ref: 54-OR1023304

BPR1K871

CAS: 2443767-35-7

BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of

Formel: C₂₅H₂₈ClN₇O₂S

Farbe und Form: Solid

Molekulargewicht: 526.054

Ref: TM-T10592

BPR1K871

CAS: 2443767-35-7

Formel: C₂₅H₂₈ClN₇O₂S

Reinheit: 98.45%

Molekulargewicht: 526.0535

Ref: IN-DA01TP4J

BPR1K871

CAS: 2443767-35-7

BPR1K871 is a synthetic, orally bioavailable anticancer compound that has potent anticancer activity. It is a multi-kinase inhibitor that inhibits the activity of aurora kinases A and B, AKT, ERK1/2, and JNK. BPR1K871 also inhibits the enzymatic activity of PDGFRβ kinase, which is involved in the proliferation of cancer cells. BPR1K871 has been shown to have no significant impurities and is stable in human plasma. This compound has been shown to have potent anticancer activity in preclinical studies with no toxicity to normal cells.

Formel: C₂₅H₂₈ClN₇O₂S

Reinheit: Min. 95%

Molekulargewicht: 526.1 g/mol

Ref: 3D-TXD76735